MS-2050

A study aims to evaluate the effectiveness of a new proton pump inhibitor (PPI) in older adults who are on aspirin therapy. The new PPI is administered to 120 patients, while the standard PPI is given to a control group of 240 individuals. During a five-year follow-up, 24 patients in the new PPI group experienced upper gastrointestinal bleeding, whereas 60 patients in the standard PPI group had the same outcome. What is the absolute risk reduction?